Opinion — anti-infectives: Where will new antibiotics come from?

By C. Walsh. Nature Reviews Microbiology, 2003

737 citations recorded by the source corpus.

Subfields: Molecular Biology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/d9c2f68b967eadf0ec14b255fc7e041923adb8cf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pharmacology

Citations in the corpus

Review on plant antimicrobials: a mechanistic viewpoint (2019, background): “Important classes of antibiotics such as macrolides, tetracyclines, aminoglycosides, and oxazolidinones show antibacterial activities through this particular mechanism [17].”
Use of Ichip for High-Throughput In Situ Cultivation of “Uncultivable” Microbial Species (2010, background): “The cultivable microbial species are widely considered overmined for secondary metabolites (2, 38), and the probability of discovery of a novel bioactive compound is low.”
Towards Advances in Medicinal Plant Antimicrobial Activity: A Review Study on Challenges and Future Perspectives (2021, background): “It also interferes with the part that interacts with the wobbling base of the tRNA anticodon [54].”
The rhizosphere as a reservoir for opportunistic human pathogenic bacteria. (2005, background): “Another important virulence feature of many human pathogenic bacteria is their resistance towards a broad range of antibiotics (Walsh, 2003).”
Loss of soil microbial diversity exacerbates spread of antibiotic resistance (2019, background): “4.3 Implications The failure of antibiotic treatments is typically attributed to the “weapon-shield” role that ARGs play in clinical settings (Martínez, 2008), and the pace of development of novel antibiotics is now alarmingly slow (Walsh, 2003).”
Management Options for Reducing the Release of Antibiotics and Antibiotic Resistance Genes to the Environment (2013, background): “In many areas of the world there are no effective anti biotic therapies available for life-threatening infections, and the pace of development of novel anti biotics is now alarmingly low (Walsh 2003).”
A common mechanism of cellular death induced by bactericidal antibiotics. (2007, neutral): “Current antimicrobial therapies, which cover a wide array of targets (Walsh, 2003), fall into two general categories: bactericidal drugs, which kill bacteria with an efﬁciency of >99.9%, and bacteriostatic drugs, which merely inhibit growth (Pankey and Sabath, 2004).”
Discovery of a structural class of antibiotics with explainable deep learning (2023, background): “This challenge has manifested in the 38-year interval between the introduction of the fluoroquinolone class of antibiotics in 1962 and the next new structural class, the oxa-zolidinones, in 2000 44 .”
Computer-Aided Drug Design Methods (2017, background): “Contributing to this is the steady rise of antibiotics drug resistance leading to the need for new antibiotics (1, 2).”